Loading news...
Rose's Income Garden portfolio reached an all-time high, with forward yield dipping slightly to 6% as portfolio value increased. Mastercard stands out with a 14.5% dividend raise, attractive valuation (P/E 26.41 vs. 5-year 34.81x), and robust earnings growth, making it a core hold. Bristol Myers Squibb and AbbVie are both considered holds due to disappointing or modest dividend raises and valuations above historical norms.
111 Capital acquired a new stake in shares of Bristol Myers Squibb Company (NYSE: BMY) in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 20,038 shares of the biopharmaceutical company's stock, valued at approximately $904,000. Several other institutional investors
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Announces Dividend.
Bristol Myers rides growth brands like Opdivo and Reblozyl to offset generics, with pipeline catalysts and cost cuts shaping its next phase.
Bristol-Myers Squibb Company (BMY) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Bristol Myers Squibb is operating in the shadow of the hype surrounding GLP-1 drugs. The company has an attractive and well-supported yield.
In the latest trading session, Bristol Myers Squibb (BMY) closed at $62.37, marking a +2.08% move from the previous day.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Shifting from higher-risk assets to consistent income sources is a natural progression for retirees.
REDMOND, Wash. & PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Patients--SystImmune and BMS Highlight Positive Phase III Interim Topline Results for izalontamab brengitecan (Iza-bren) in Previously-Treated Unresectable.
Cary Street Partners Financial LLC grew its stake in Bristol Myers Squibb Company (NYSE: BMY) by 11.6% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 106,445 shares of the biopharmaceutical company's stock after purchasing an additional 11,086 shares
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
While many Baby Boomers have enjoyed a long bull market over the past 35 years, there is a point when income becomes more critical than stock appreciation.
NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, Feb. 25, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor.
First Financial Bankshares Inc acquired a new position in shares of Bristol Myers Squibb Company (NYSE: BMY) in the third quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 9,522 shares of the biopharmaceutical company's stock, valued at approximately $429,000. A number of other large investors also
Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Participate in the TD Cowen 46th Annual Health Care Conference.
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb Announces Positive Top-Line Results from Registrational Phase 2 Study of Luspatercept in Adults with Alpha (α)-Thalassemia.
Citigroup Inc. reduced its position in Bristol Myers Squibb Company (NYSE: BMY) by 30.7% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 2,707,893 shares of the biopharmaceutical company's stock after selling 1,197,195 shares during the quarter. Citigroup Inc. owned about 0.13% of
Multiple core drugs are losing patent protection over the coming years, carving an eventual crater in revenue. Newer, growing drugs should help fill that hole, and Cobenfy is a wild card with huge potential.